ACTG A5142 LOPINAVIR/RITONAVIR PLUS EFAVIRENZ FOR HIV-1 INFECTION

ACTG A5142 洛匹那韦/利托那韦加依非韦伦治疗 HIV-1 感染

• 批准号: 7374177
• 负责人: RICHARD H HAUBRICH
• 金额: $ 1.17万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7374177
• 关键词: efavirenz; infection; lamivudine; limbs; lipodystrophy; lopinavir; ritonavir; stavudine; success; zidovudine

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Compare the time to virologic failure pairwise in HIV 1 between the three treatments groups, (1) Lopinavir/Ritonavir plus Efavirenz, (2) Lopinavir/Ritonavir plus Stavudine Extended Release (or Zidovudine) plus Lamivudine or (3) Efavirenz plus Stavudine Extended Release (or Zidovudine) plus Lamivudine. Compare time to regimen completion pairwise between the 3 treatment groups. Regimen completion will be defined as either virologic failure or toxicity-related discontinuation of any component of the initial randomized treatment regimen. Compare treatment groups occurrence of peripheral lipoatrophy as measured by limb DEXA. Compare groups on metabolic abnormalities.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。比较三个治疗组（1）洛匹那韦/利托那韦+依法韦仑，（2）洛匹那韦/利托那韦+司他夫定缓释剂（或齐多夫定）+拉米夫定或（3）依法韦仑+司他夫定缓释剂（或齐多夫定）+拉米夫定）之间HIV 1病毒学失败的时间。比较3个治疗组之间至方案完成的时间。方案完成将定义为病毒学失败或初始随机化治疗方案任何组分的毒性相关停药。通过肢体DEXA测量，比较治疗组外周脂肪萎缩的发生率。比较各组代谢异常情况。